120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
胎盘多肽注射液中胚层疗法治疗中重度敏感性皮肤的安全性和疗效：一项多中心随机对照试验
Authors Shu C , Zhang XY, Han XF, Liu JW, Sun X, Sun QN
Received 12 September 2025
Accepted for publication 17 January 2026
Published 29 January 2026 Volume 2026:19 567103
DOI https://doi.org/10.2147/CCID.S567103
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Rungsima Wanitphakdeedecha
Chang Shu,1 Xin-Yu Zhang,2 Xue-Feng Han,2 Jia-Wei Liu,1 Xin Sun,1 Qiu-Ning Sun1
1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China; 2Department of Body Contouring and Liposuction Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100144, People’s Republic of China
Correspondence: Qiu-Ning Sun, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China, Tel +86-10-69151502, Email sunqn@pumch.cn
Background: Sensitive skin (SS) is a prevalent condition characterized by cutaneous hyperreactivity and neurosensory inflammation, for which effective treatments remain limited. Placenta polypeptide injection (PPI), rich in anti-inflammatory cytokines and growth factors, presents a promising therapeutic candidate. This study aimed to rigorously evaluate the safety and efficacy of mesotherapy with PPI for treating moderate-to-severe SS.
Methods: In this multicenter, open-label, randomized controlled trial, 156 adults with moderate-to-severe SS were randomized (PPI group: control group = 2:1) to receive three sessions of mesotherapy with PPI (4 mL per session at 30-day intervals) or no treatment (control group) over a 90-day period. The primary endpoint was the change in total facial skin hemoglobin content, a proxy measure of cutaneous inflammation, from baseline to Day 90, quantified by a 3D skin analysis system. Safety was monitored through adverse events (AEs) and laboratory assessments.
Results: A total of 154 patients were included in the full analysis set (FAS; 103 PPI group, 51 control group). At Day 90, the PPI group demonstrated a significantly greater reduction in skin hemoglobin content compared to the control group (mean change, − 1705.82 ± 1808.17 vs − 756.65 ± 1493.17; P=0.001). Furthermore, a significantly higher proportion of patients in the PPI group reported aesthetic improvement on the GAIS (88.9% vs 5.9% rated as “improved” to “very much improved”; P < 0.001). The incidence of AEs was comparable between the PPI (5.8%) and control (9.6%) groups (P = 0.376), with no serious AEs reported.
Conclusion: Mesotherapy with placenta polypeptide injection is an effective and safe treatment for moderate-to-severe sensitive skin, leading to significant reductions in cutaneous inflammation metrics and high rates of patient-reported aesthetic improvement.
Trial Registration: This study was prospectively registered at Chinese Clinical Trial Registry (No. ChiCTR2400080988, Date: 20/02/2024).
Keywords: sensitive skin, placenta polypeptide injection, mesotherapy, inflammation, randomized controlled trial, hemoglobin content
1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China; 2Department of Body Contouring and Liposuction Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100144, People’s Republic of China
Correspondence: Qiu-Ning Sun, Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China, Tel +86-10-69151502, Email sunqn@pumch.cn
Background: Sensitive skin (SS) is a prevalent condition characterized by cutaneous hyperreactivity and neurosensory inflammation, for which effective treatments remain limited. Placenta polypeptide injection (PPI), rich in anti-inflammatory cytokines and growth factors, presents a promising therapeutic candidate. This study aimed to rigorously evaluate the safety and efficacy of mesotherapy with PPI for treating moderate-to-severe SS.
Methods: In this multicenter, open-label, randomized controlled trial, 156 adults with moderate-to-severe SS were randomized (PPI group: control group = 2:1) to receive three sessions of mesotherapy with PPI (4 mL per session at 30-day intervals) or no treatment (control group) over a 90-day period. The primary endpoint was the change in total facial skin hemoglobin content, a proxy measure of cutaneous inflammation, from baseline to Day 90, quantified by a 3D skin analysis system. Safety was monitored through adverse events (AEs) and laboratory assessments.
Results: A total of 154 patients were included in the full analysis set (FAS; 103 PPI group, 51 control group). At Day 90, the PPI group demonstrated a significantly greater reduction in skin hemoglobin content compared to the control group (mean change, − 1705.82 ± 1808.17 vs − 756.65 ± 1493.17; P=0.001). Furthermore, a significantly higher proportion of patients in the PPI group reported aesthetic improvement on the GAIS (88.9% vs 5.9% rated as “improved” to “very much improved”; P < 0.001). The incidence of AEs was comparable between the PPI (5.8%) and control (9.6%) groups (P = 0.376), with no serious AEs reported.
Conclusion: Mesotherapy with placenta polypeptide injection is an effective and safe treatment for moderate-to-severe sensitive skin, leading to significant reductions in cutaneous inflammation metrics and high rates of patient-reported aesthetic improvement.
Trial Registration: This study was prospectively registered at Chinese Clinical Trial Registry (No. ChiCTR2400080988, Date: 20/02/2024).
Keywords: sensitive skin, placenta polypeptide injection, mesotherapy, inflammation, randomized controlled trial, hemoglobin content